Skip to main content

Table 1 Patient and tumor characteristics

From: Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study

Patient demographic information/tumor characteristics

Case (%)

Sex

 Male

18 (60.00)

 Female

12 (40.00)

Age (years)

 < 60

7 (23.33)

 â‰Ąâ€‰60

23 (76.67)

ECOG performance status

 0

19 (63.33)

 1

8 (26.67)

 2

3 (10.00)

Tumor size (cm)

 < 5.0

16 (53.33)

 â‰Ąâ€‰5.0

14 (46.67)

Differentiation

 Poor

13 (43.33)

 Moderately or well

17 (56.67)

Lesion site

 Cardia

10 (33.33)

 Stomach

6 (20.00)

 Gastric antrum

10 (33.33)

 Whole stomach

4 (13.33)

cT stage

 T3

8 (26.67)

 T4

22 (73.33)

PD-L1 overexpression(CPS)

 < 1

11 (36.67)

≧ 1

19 (63.33)